CRIMINI, EDOARDO
CRIMINI, EDOARDO
Dipartimento di Oncologia ed Emato-Oncologia
Molecular tumor board in patients with metastatic breast cancer
2025 L. Boscolo Bielo, E. Guerini Rocco, E. Crimini, M. Repetto, M. Lombardi, C. Zanzottera, G. Aurilio, M. Barberis, C. Belli, Y. Zhan, E. Battaiotto, J. Katrini, R. Marsicano, P. Zagami, B. Taurelli Salimbeni, A. Esposito, D. Trapani, C. Criscitiello, N. Fusco, A. Marra, G. Curigliano
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
2024 L. Mazzarella, F. Giugliano, E. Nicolo, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. D'Amico, P.T. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P.P.M. Berton Giachetti, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience
2024 E. Crimini, G. Tini, P. Tarantino, L. Ascione, M. Repetto, P. Beria, A. Ranghiero, A. Marra, C. Belli, C. Criscitiello, A. Esposito, E. Guerini Rocco, M.C.P. Barberis, L. Mazzarella, G. Curigliano
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit
2024 A. Esposito, E. Crimini, C. Criscitiello, C. Belli, R. Scafetta, R. Scalia, G. Castellano, E. Giordano, J. Katrini, L. Ascione, L. Boscolo Bielo, M. Repetto, A. Marra, D. Trapani, G.M. Varano, D. Maiettini, P. Della Vigna, F. Orsi, E. Guerini Rocco, N. Fusco, G. Curigliano
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations
2024 L. Boscolo Bielo, E. Guerini Rocco, D. Trapani, P. Zagami, B. Taurelli Salimbeni, A. Esposito, C. Belli, E. Crimini, K. Venetis, E. Munzone, N. Fusco, C. Criscitiello, A. Marra, G. Curigliano
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers
2024 C. Belli, L. Boscolo Bielo, M. Repetto, E. Crimini, R. Scalia, A. Diana, J. Orefice, L. Ascione, G. Pellizzari, N. Fusco, M. Barberis, B. Daniele, E. Guerini-Rocco, G. Curigliano
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology
2024 L. Boscolo Bielo, C. Belli, E. Crimini, M. Repetto, L. Ascione, G. Pellizzari, C. Santoro, V. Fuorivia, M. Barberis, N. Fusco, E.G. Rocco, G. Curigliano
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis
2024 L. Boscolo Bielo, M. Repetto, E. Crimini, C. Belli, E. Setola, G. Parma, N. Fusco, M. Barberis, E. Guerini Rocco, A. Marra, N. Colombo, G. Curigliano
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
2023 G. Spitaleri, P. Trillo Aliaga, I. Attili, E. Del Signore, C. Corvaja, C. Corti, E. Crimini, A. Passaro, F. de Marinis
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience
2023 M. Repetto, E. Crimini, L. Boscolo Bielo, E. Guerini-Rocco, L. Ascione, A. Bonfanti, C. Zanzottera, L. Mazzarella, A. Ranghiero, C. Belli, C. Criscitiello, A. Esposito, M.C.P. Barberis, G. Curigliano
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
2023 L. Ascione, E. Crimini, D. Trapani, A. Marra, C. Criscitiello, G. Curigliano
Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?
2023 D. Trapani, E. Crimini, J. Sandoval, G. Curigliano
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population
2022 L. Mazzarella, E. Nicolò, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. Trillo Aliaga, C. Valenza, M. Repetto, G. Antonarelli, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents
2022 P. Tarantino, O. D'Ecclesiis, E. Nicolò, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M.A. Locatelli, C. Belli, A. Esposito, I. Minchella, S.M. Tolaney, G. Curigliano
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
2022 K. Venetis, E. Crimini, E. Sajjadi, C. Corti, E. Guerini-Rocco, G. Viale, G. Curigliano, C. Criscitiello, N. Fusco
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population
2022 L. Mazzarella, F. Giugliano, E. Nicolo', E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, I. Minchella, C. Belli, A. Esposito, M. Locatelli, C. Criscitiello, G. Curigliano
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
2022 S. Morganti, A. Marra, E. Crimini, P. D'Amico, P. Zagami, G. Curigliano
PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
2022 L. Ascione, P. Zagami, E. Nicolò, E. Crimini, G. Curigliano, C. Criscitiello
Benefit of adjuvant chemotherapy in patients with lobular breast cancer : A systematic review of the literature and metanalysis
2021 D. Trapani, S. Gandini, C. Corti, E. Crimini, F. Bellerba, I. Minchella, C. Criscitiello, P. Tarantino, G. Curigliano